Migraine prevalence in China is rapidly growing due to the increasing population of patients affected in combination with the swift change of the society towards a modern industrialized country lifestyle.
The current market size for specific anti-migraine preparations is still very limited in China as disease awareness amongst patients and doctors is scarce and differentiated diagnosis is still very limited, but its growth rate is significant (+117%) as underdiagnoses reduces. Moreover, the main drugs available specific for migraine therapy are standard triptans (either branded or generics), thus leaving unaddressed the need of a fast effective and tolerable treatment.
APR’s unique and exclusive formulation of Diclofenac, based on the APR’s patented Dynamic Buffering Technology (“DBT”), is particularly suitable for the management of migraine, by securing faster pain relief, rapid onset of action and sustained pain-free, thus reducing recurrence of migraine attacks associated with a favourable side-effect profile and projecting this product to be the first NSAID specifically approved for migraine in China, thus replicating the same success story APR was able to achieve in the USA.
APR’s Diclofenac drugs, including DBT based ones, are currently marketed and promoted in several countries all over the world, thanks to a wide network of partners, such as Novartis AG and Depomed.
Approximately 100 million doses of APR’s Diclofenac DBT are sold every year, confirming the distinctive and exclusive competitive advantage of APR’s formulation over conventional preparations.
Diclofenac powder for oral solution has been recently established as “effective” (Level A) for the therapy of acute migraine attacks by the AHS (America Headache Society), following an evidence-based assessment via a systematic review of Class I.